B. Riley Wealth Advisors Inc. Has $572,000 Stake in DaVita Inc. (NYSE:DVA)

B. Riley Wealth Advisors Inc. grew its position in shares of DaVita Inc. (NYSE:DVA) by 78.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,130 shares of the company’s stock after buying an additional 1,822 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in DaVita were worth $572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Blue Trust Inc. lifted its holdings in shares of DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of DaVita during the 4th quarter valued at about $30,000. Family Firm Inc. acquired a new stake in shares of DaVita during the 2nd quarter valued at about $43,000. Versant Capital Management Inc lifted its holdings in DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after purchasing an additional 155 shares during the last quarter. Finally, Friedenthal Financial acquired a new stake in DaVita in the 2nd quarter worth approximately $48,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other DaVita news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now owns 905,659 shares of the company’s stock, valued at approximately $141,219,407.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares in the company, valued at $12,137,038.31. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock valued at $27,387,069 over the last 90 days. 2.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. Truist Financial boosted their price objective on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Tuesday, August 20th. TD Cowen boosted their price objective on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. UBS Group upped their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, DaVita has an average rating of “Hold” and an average target price of $157.00.

DaVita Price Performance

DaVita stock opened at $160.69 on Friday. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The firm has a market cap of $14.09 billion, a P/E ratio of 18.26, a P/E/G ratio of 0.91 and a beta of 0.87. The business’s fifty day moving average is $152.14 and its two-hundred day moving average is $142.92. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $166.04.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. During the same quarter in the prior year, the firm posted $2.08 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. Equities research analysts forecast that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.